Table 3.
Pharmacokinetic consequences of CYP2D6 polymorphism
| Pharmacokinetic parameter | Consequences for the PM relative to EM |
|---|---|
| Bioavailability | 2–5-fold |
| Systemic exposure | |
| Cmax | 2–6-fold |
| AUC | 2–5-fold |
| Half-life | 2–6-fold |
| Metabolic clearance | 0.1–0.5-fold |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.